🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 48 of 173

  1. US 10758642

    Sterilization process

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10758632

    NIR-conjugated tumor-specific antibodies and uses thereof

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10758496

    Estrogen receptor ligand treatment for neurodegenerative diseases

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10758513

    Modulators of mitochondrial protein import

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10758600

    Fungal immunogens and related materials and methods

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10752639

    Bridged bicyclic inhibitors of menin-MLL and methods of use

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10751533

    Regulation of autonomic control of bladder voiding after a complete spinal cord injury

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10751416

    IL-26 inhibitors

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10751281

    Auris formulations for treating otic diseases and conditions

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10752920

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10751428

    Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10752882

    Compositions and methods for treating retinal diseases

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10751347

    Compositions comprising acidic extracts of mastic gum and uses thereof for treating optic neuropathy

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10751348

    Formulations of testosterone and methods of treatment therewith

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10751408

    Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10752699

    Anti-APOBEC3 antibodies and methods of making and using

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10752581

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10751409

    Immunogenic compositions and uses thereof

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10744232

    Antimicrobial catheters

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10744116

    Detection and treatment of anti-PD-1 therapy resistant metastatic melanomas

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10745366

    Therapeutic compounds

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10744230

    Biomimetic hybrid gel compositions and methods of use

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10745453

    Compositions and methods for enhancing visual function

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10745464

    Aldehyde tags, uses thereof in site-specific protein modification

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10745474

    Methods of treating inflammation associated airway diseases and viral infections

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10746738

    Claudin-1 peptide reagents and methods

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10745420

    Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10738123

    Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10738113

    Anti-IL-2 antibodies and compositions and uses thereof

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10738043

    GLS1 inhibitors for treating disease

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10736880

    Therapeutics for preterm labor management

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10736864

    Immunotherapeutic agent

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10736989

    Methods and compositions for stabilizing the myocardium

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10738081

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10729668

    Ketobutyrate compounds and compositions for treating age-related symptoms and diseases

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10730848

    Protective molecules against anthrax toxin

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10729693

    Compositions and methods for the treatment of endometriosis

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10729747

    Methods and compositions for modulating myofibroblast activities

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10730871

    Immunomodulators and immunomodulator conjugates

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10730842

    Small molecule inhibitors of DYRK1A and uses thereof

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10729753

    Compositions and methods for treatment of homocystinuria

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10729788

    Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10729641

    Ordered macroporous materials

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10729643

    Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10729781

    LGR4 specific monoclonal antibodies and methods of their use

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10729895

    Active agent delivery devices and methods of using the same

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10722487

    Glutaminase inhibitor therapy

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10722537

    Activation of resident memory T cells for cancer immunotherapy

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.